Attached files

file filename
EX-99.4 - EXHIBIT 99.4 - Shire plcdecember242018-holdingcoxe.htm
EX-99.3 - EXHIBIT 99.3 - Shire plcdecember242018-rule29xexhi.htm
EX-99.1 - EXHIBIT 99.1 - Shire plcdecember212018-holdingcoxe.htm
8-K - 8-K - Shire plca8-kxdecember262018file.htm


EXHIBIT 99.2

Press Release
shirelogobluergba81.jpg
www.shire.com
 


Director Declaration

December 21, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ian Clark, Non-Executive Director of the Company, is a Non-Executive Director of Guardant Health, Inc which became publically quoted on October 4, 2018.

This disclosure is made pursuant to LR 9.6.14 of the UK Listing Rules.

Sarah Rixon
Senior Company Secretarial Assistant


For further information please contact:

Investor Relations
 
 
Christoph Brackmann
christoph.brackmann@shire.com
+41 41 288 41 29
Sun Kim
sun.kim@shire.com
+1 617 588 8175
Scott Burrows
scott.burrows@shire.com
+41 41 288 4195
 
 
 
Media
 
 
Katie Joyce
kjoyce@shire.com
+1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
  
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.


www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX